Tumor Biopsy
A biopsy may be taken at the time of a patient’s initial tumor treatment (ocular melanoma), and it is highly recommended for accurate diagnosis and personalized care planning in cases of ocular melanoma. The newly diagnosed patient should inquire with their treating surgeon or oncologist about obtaining a fine-needle biopsy. This minimally invasive procedure collects tumor material, which can then be used for prognostic testing to assess the likelihood of the tumor spreading to other parts of the body.
One of the leading options for prognostic testing in ocular melanoma is offered by Castle Biosciences, which provides a specialized test to determine the “Class” of the tumor. Tumors are categorized as either Class 1 or Class 2, with Class 1 tumors being the least aggressive and Class 2 tumors being the most aggressive. This classification is a critical tool in guiding follow-up care, including setting a schedule for regular scans and blood work during the first few years after initial treatment.
Additionally, further testing can be conducted using the same biopsy sample. Tests like PRAME (Preferentially Expressed Antigen in Melanoma) testing and DNA sequencing provide deeper insights into the tumor’s characteristics. DNA sequencing can identify specific gene mutations associated with the patient’s ocular melanoma. This knowledge not only enhances understanding of the tumor’s behavior but also helps connect patients with clinical trials and potential personalized targeted therapies that align with their unique genetic profile.
Impact Genetics is another provider offering prognostic testing for ocular melanoma, including assessments that determine key tumor attributes. These tests contribute to a more comprehensive approach to managing the disease and planning treatment strategies. As with any treatment or diagnostic approach, patients are encouraged to seek second opinions to ensure they explore all available options for care.
For more detailed information about the prognostic tests available for uveal melanoma patients, click the links below: